Dohj LLC Purchases 182 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dohj LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,520 shares of the medical research company’s stock after acquiring an additional 182 shares during the period. Dohj LLC’s holdings in IQVIA were worth $1,085,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $1,616,000. Simplify Asset Management Inc. increased its position in IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Finally, Versor Investments LP acquired a new stake in shares of IQVIA in the third quarter valued at approximately $1,328,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of several research reports. The Goldman Sachs Group decreased their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Price Performance

NYSE IQV opened at $201.34 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.54 billion, a price-to-earnings ratio of 26.42, a PEG ratio of 2.12 and a beta of 1.48. The business has a 50 day simple moving average of $200.41 and a 200 day simple moving average of $220.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.